Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Moderate Buy" from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $56.57.

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank lifted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, December 9th. Royal Bank of Canada increased their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 10th. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. Finally, StockNews.com cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th.

Remove Ads

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded down $1.55 during trading on Friday, hitting $30.76. 355,336 shares of the company were exchanged, compared to its average volume of 682,991. The business's 50-day simple moving average is $33.34 and its 200 day simple moving average is $41.20. Agios Pharmaceuticals has a twelve month low of $27.14 and a twelve month high of $62.58. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of 2.71 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, equities analysts forecast that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares of the company's stock, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.93% of the company's stock.

Institutional Trading of Agios Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Venturi Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at $33,000. GF Fund Management CO. LTD. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at about $39,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at about $53,000. Sterling Capital Management LLC increased its stake in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after acquiring an additional 1,587 shares during the period. Finally, Quest Partners LLC raised its position in Agios Pharmaceuticals by 139.6% in the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,283 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.